natgillin/translations-raw huggingface dataset:
The DNase of any of claims 1 to 8, for use in the treatment of human female infertility, wherein at least 2500 UI of DNase 1 are administered each day to an infertile woman, during at least 4 days. 
DNaza prema bilo kojem od patentnih zahtjeva 1 do 8, za uporabu u liječenju neplodnosti žena, pri čemu se najmanje 2500 UI DNaze 1 primjenjuje svakog dana na neplodnu ženu, u toku najmanje 4 dana.
method for in vitro diagnosing infertility in a mammalian female, comprising the following steps: 
Postupak za in vitro dijagnozu neplodnosti kod jedinke sisavca ženskog spola, koji sadrži slijedeće korake:
determining the level of cell-free DNA in a body fluid sample from said female, and 
određivanje razine bezstanične DNK u uzorku tjelesne tekućine iz navedene jedinke ženskog spola, i
The method of claim 11 or claim 12, wherein the body fluid sample is a sample of plasma, serum, blood or follicular fluid. 
Postupak prema patentnom zahtjevu 11 ili patentnom zahtjevu 12, naznačen time što, uzorak tjelesne tekućine je uzorak plazme, seruma, krvi ili folikularne tekućine.
The kit according to claim 16. comprising at least a DNA intercalating agent and an antibody specifically recognizing AMH. 
Kit prema patentnom zahtjevu 16, koji sadrži najmanje DNK-interkalirajući agens i antitijelo koje specifično prepoznaje AMH.
The control valve according to claim 1 or 2, characterized in that said cavity (80) housing the sealing gasket (82) extends along an inclined surface of the petal (6, 6') which is contacted by a cooperating inclined surface of the adjacent petal (7, 7'). 
Kontrolni ventil prema zahtjevu 1 ili 2, naznačen time da spomenuta šupljina (80) smještena na brtvilo (82) proteže se uzduž nagnute površine krilca (6, 6’)koji je spojen zajedno s nagnutom površinom susjednog krilca (7, 7’).
and R2 independently of one another represent hydrogen, aminocarbonyl or (C1-C4)-alkyl, or 
i R2 međusobno neovisno predstavljaju vodik, aminokarbonil ili (C1-C4)-alkil, ili
and R2 together with the carbon atom to which they are bonded form a (C3-C8)-cycloalkyl, 
i R2 zajedno s atomom ugljika na kojeg su vezani tvore (C3-C8)-cikloalkil,
and R2 independently of one another represent hydrogen or (C1-C4)-alkyl, or 
i R2 međusobno neovisno predstavljaju vodik ili (C1-C4)-alkil, ili
Q represents a bond, k represents an integer 1 or 2, and * is the linkage site to the residue represented by A, and whereby phenyl und heteroaryl further may be substituted with one or two substituents selected independently of one another from the group consisting of halogen, cyano, amino, hydroxy, (C1-C4)-alkyl or hydroxy-(C1-C4)-alkyl, 
b predstavlja vodik, Q predstavlja vezu, k predstavlja cijeli broj 1 ili 2, i * je mjesto vezanja na ostatak kojeg predstavlja A, te gdje fenil i heteroaril mogu biti dodatno supstituirani s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine halogen, cijano, amino, hidroksi, (C1-C4)-alkil ili hidroksi-(C1-C4)-alkil, gdje pak hidroksialkil može biti supstituiran s karbonilnim supstituentom, i I predstavlja 0 i njegove soli, njegovi solvati i solvati njegovih soli.
and R2 independently of one another represent hydrogen or methyl, 
i R2 međusobno neovisno predstavljaju vodik ili metil,
Method for the preparation of a compound of formula (I) according to claim 1, comprising removing the protecting group from a compound of formula in which Pg represents a protecting group and R1-R3, A, I, X, Y and Z are as defined in claim 1. 
Postupak priprave spoja formule (I) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u uklanjanju zaštitne skupine iz spoja formule [image], gdje Pg predstavlja zaštitnu skupinu, a R1-R3, A, I, X, Y i Z su definirani kao u patentnom zahtjevu 1.
Method according to claim 12, characterized in that compound (II) is prepared by reacting a compound of formula in which Pg represents a protecting group and A, I, X, Y and Z are as defined in claim 1, with a compound of formula in which R1, R2 and R3 are as defined in claim 1. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se spoj (II) pripravlja reakcijom spoja formule [image], gdje Pg predstavlja zaštitnu skupinu, a A, I, X, Y i Z su definirani kao u patentnom zahtjevu 1, sa spojem formule [image], gdje su R1, R2 i R3 definirani kao u patentnom zahtjevu 1.
Medicament comprising at least one compound according to any one of claims 1 to 8 in combination with at least one inert, non-toxic, pharmaceutically acceptable excipient. 
Medikament, naznačen time što sadrži najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, u kombinaciji s najmanje jednom inertnom, netoksičnom, farmaceutski prihvatljivom pomoćnom tvari.
Medicament according to any one of claims 16 to 18 for use in a method of treating and/or preventing bacterial infections. 
Medikament u skladu s bilo kojim od patentnih zahtjeva 16 do 18, naznačen time što je namijenjen upotrebi u postupku liječenja i/ili sprječavanja bakterijskih infekcija.
A liquid agent for surface treatment with high photocatalytic and sanitary effects, based on TiO2 nanoparticles, characterized by the fact that it contains 10g to 500g of the TiO2 nanoparticles per 1 liter of water, and a binding ingredient A, which is an inorganic binder selected from the group comprising ZnO, MgO, CaO, Ca(OH)2, Mg(OH)2, CaCO3, MgCO3, Na2CO3, and K2CO3 in the amount of 0.1 to 10 % by weight related to the TiO2 nanoparticles weight content. 
Tekuće sredstvo za površinsko tretiranje s visokim fotokatalitičkim i sanitarnim učinkom, na bazi nanočestica TiO2, naznačeno time da sadrži od 10 g do 500 g nanočestica TiO2 po 1 litri vode i vezivni sastojak A, koji je anorgansko vezivo odabrano iz skupine koja obuhvaća ZnO, MgO, CaO, Ca(OH)2, Mg(OH)2, CaCO3, MgCO3, Na2CO3, i K2CO3u količini od 0,1 do 10 % mase u odnosu na maseni udio nanočestica TiO2.
A method of preparation of the liquid agent for surface treatment according to claim 1, characterized by the fact that the TiO2 nanoparticles are mixed with water, and the aqueous suspension created during intensive homogenization is mixed with the solution or suspension of the binding ingredient A at the temperature 5 to 50°C, instantly after the addition of the binding ingredient A the suspension strongly thickens. 
Metoda pripremanja tekućeg sredstva za površinsko tretiranje prema iz zahtjeva 1, naznačena time da se nanočestice TiO2 miješaju s vodom, a vodena suspenzija nastala tijekom intenzivne homogenizacije miješa se s otopinom ili suspenzijom vezivnog sastojka A na temperaturi od 5 do 50 °C, odmah nakon dodavanja vezivnog sastojka A suspenzija se jako zgušnjava.
A method of surface treatment characterized by the fact that the liquid agent according to claim 1 is applied onto the surface at the temperature of 5 to 50°C in the thickness of 1 to 50 micrometers and after drying created dry layer contains a minimum of 90% by weight of the TiO2 nanoparticles. 
Metoda površinskog tretiranja naznačena time da se tekuće sredstvo iz zahtjeva 1 primjenjuje na površinu pri temperaturi od 5 do 50°C u sloju debljine od 1 do 50 mikrometara te nakon sušenja nastali suhi sloj sadrži najmanje 90 % mase nanočestica TiO2.
The method of surface treatment according to claim 3 characterized by the fact that the liquid agent according to claim 1 is applied onto the surface at the temperature of 5 to 50°C in the thickness of 5 to 30 micrometers 
Metoda površinskog tretiranja iz zahtjeva 3 naznačena time da se tekuće sredstvo iz zahtjeva 1 primjenjuje na površinu pri temperaturi od 5 do 50°C u sloju debljine od 5 do 30 mikrometara
electrochemically generating I+ cations from a suitable iodine source in a solvent at the anodic compartment, the same or different for steps (a) and (b), selected from: acetonitrile, lower alcohols C1-C4 or mixtures thereof; and 
elektrokemijsko generiranje I+ kationa iz odgovarajućeg izvora joda u otapalu na anodnom dijelu, isto ili različito za korake (a) i (b), koji se bira od: acetonitrila, nižih alkohola C1-C4 ili njihovih smjesa; te
iodinating 3,5-disubstituted-phenols of formula (1) in the presence of the above I+ cations of step (a): wherein R and R' represent, the same or different from each other, a group selected from carboxy -COOH, carboxyester -COOR1 and carboxamido -CONH2, -CONHR1 or -CONR2R3; wherein 
jodiranje 3,5-disupstituiranih-fenola s formulom (1) u prisutnosti gornjih I+ kationa iz koraka (a): [image] naznačen time da R i R' predstavljaju, isto ili različito jedan od drugog, skupinu odabranu od karboksi -COOH, karboksiester-COOR1 i karboksamido-CONH2, -CONHR1 ili -CONR2R3; pri čemu
The process according to claim 8 wherein the resulting solution of step (a) is transferred in a separate reactor and contacted with the compound of formula (1) or a solution thereof. 
Postupak prema zahtjevu 8 naznačen time da se dobivena otopina iz koraka (a) prebacuje u odvojeni reaktor i dovodi u kontakt sa spojem s formulom (1) ili s njegovom otopinom.
The process according to claims 10 or 11 for the preparation of a compound of formula (5) wherein both R and R' are a -CONH-CH(CH2OH)2 group, R4 is hydrogen and R5 is methyl. 
Postupak prema zahtjevima 10 ili 11 naznačen time da je za pripremanje spoja s formulom (5) pri čemu oba R i R' su skupina -CONH-CH(CH2OH)2, R4 je vodik i R5 je metil.
The process according to claims 10 or 11 for the preparation of a compound of formula (5) wherein both R and R' represent a -CONH-CH2-CH(OH)CH2OH group, R4 is methyl and R5 is hydrogen. 
Postupak prema zahtjevima 10 ili 11 naznačen time da je za pripremanje spoja s formulom (5) pri čemu oba R i R' predstavljaju skupinu -CONH-CH2-CH(OH)CH2OH, R4 je metil i R5 je vodik.
The process for the preparation of Iopamidol or Iomeprol by starting from the corresponding compound of formula (2) prepared according to the process of any one of claims 1-10. 
Postupak za pripremanje Iopamidola ili Iomeprola polazeći od odgovarajućeg spoja formule (2) dobivenog prema postupku prema bilo kojem od zahtjeva 1-10.
R5, R6 together with the phenyl group they are attached to, form benzo-1,2-dioxolyl, of which the carbon atom bridging the two oxygen atoms may be unsubstituted, or mono- or disubstituted by F or methyl, in Subformula 6 
, R6 zajedno s fenilnom skupinom na koju su vezani, tvore benzo-1,2-dioksolil, u kojima ugljikov atom koji premošćuje dva atoma kisika može biti nesupstituiran, ili jednostruko- ili dvostruko supstituiran s F ili metilom, u podformuli 6
The compound according to Claim 1, wherein the compound is selected from the group consisting of: 4-[(S)-2-Azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide; 
Spoj prema zahtjevu 1, naznačen time da je spoj odabran iz skupine koju čine: amid 4-[(S)-2-azetidin-1-il-1-(3-fluorfenil)-etilamino]-kinazolin-8-karboksilne kiseline;
The compound for use of claim 7, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the cancer is selected from a group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, or thyroid cancer, or melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma, Kaposi's sarcoma. 
Spoj za uporabu prema zahtjevu 7, i/ili njegovi stereoizomeri ili tautomeri, ili farmaceutski prihvatljive soli svakog od gore navedenih, uključujući i njihove smjese u svim omjerima, naznačen time da je rak odabran iz skupine koju čine rak mozga, rak pluća, karcinom debelog crijeva, epidermoidni karcinom, karcinom skvamoznih stanica, rak mokraćnog mjehura, karcinom želuca, karcinom gušterače, karcinom dojke, karcinom glave, karcinom vrata, karcinom bubrega, karcinom jetre, karcinom jajnika, karcinom prostate, karcinom debelog crijeva, karcinom maternice, rektalni karcinom, karcinom jajnika, karcinom testisa, karcinom ginekoloških organa, ili karcinom štitnjače, ili melanom, hematološke maligne bolesti kao što su akutna mijelogena leukemija, multipli mijelom, kronična mijelogena leukemija, leukemija mijeloidnih stanica, gliom, Kaposijev sarkom.
An antibody as defined in claim 1, which comprises a heavy chain of SEQ ID NO:62 and a light chain of SEQ ID NO:64. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac sa SEQ ID NO:62 i laki lanac sa SEQ ID NO:64.
A nucleic acid molecule as defined in claim 3, comprising SEQ ID NO:61 and SEQ ID NO:63. 
Molekula nukleinske kiseline u skladu s patentnim zahtjevom 3, naznačena time što sadrži SEQ ID NO:61 i SEQ ID NO:63.
A recombinant host cell comprising an expression vector as defined in claim 6. 
Rekombinantna stanica domaćin, naznačena time što sadrži ekspresijski vektor u skladu s patentnim zahtjevom 6.
A compound of formula (XI) or (XIa): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen atom they are linked to form a phthalimido group. 
Spoj formule (XI) ili (XIa) [image] naznačen time da R’ jest vodik, a R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R’ jest trimetilsilil, a R jest tert-butoksikarbonil; ili R i R’ uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
A compound of formula (XII): in which X is selected from Cl, Br or I and wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen atom they are linked to form a phthalimido group. 
Spoj formule (XII) [image] u kojoj je X odabran od sljedećih: Cl, Br ili I te naznačen time da R’ jest vodik i R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R’ jest trimetilsilil i R jest tert-butoksikarbonil; ili R i R’ uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
Use of a compound as claimed in claims 1-4 as an intermediate in the synthesis of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (I) or a pharmaceutically acceptable salt thereof. 
Upotreba spoja kako je prijavljen u patentnim zahtjevima 1 – 3 kao međuprodukt u sintezi 6-(7-((1-aminociklopropil)metoksi)-6-metoksikinolin-4-iloksi)-N-metil-1-naftamida (I) ili odgovarajuće farmaceutski prihvatljive soli.
A composition for use as a dialysis liquid in haemodialysis or peritoneal dialysis that comprises the crystallization inhibitory substance inositol phosphate or the pharmaceutically acceptable salts thereof. 
Pripravak za uporabu kao tekućina za dijalizu u hemodijalizi ili peritonejskoj dijalizi, a koji sadrži tvar za inhibiciju kristalizacije inozitol fosfat ili njegove farmaceutski prikladne soli.
The composition for use according to claim 3, where the inositol phosphate is inositol hexaphosphate. 
Pripravak za uporabu prema zahtjevu 3, gdje inozitol fosfat jest inozitol heksafosfat.
The composition for use according to claim 4, where the inositol phosphate is myo -inositol hexaphosphate. 
Pripravak za uporabu prema zahtjevu 4, gdje inozitol fosfat jest myo-inozitol heksafosfat.
A dialysis liquid for use in haemodialysis or peritoneal dialysis that comprises crystallisation inhibitory substances selected from the list that comprises inositol phosphate or the pharmaceutically acceptable salts thereof. 
Tekućina za dijalizu za uporabu u hemodijalizi ili peritonejskoj dijalizi, a koja sadrži tvari za inhibiciju kristalizacije odabrane s popisa koji obuhvaća inozitol fosfat ili njegove farmaceutski prikladne soli.
A combined preparation that comprises, at least, a composition that comprises crystallisation inhibitory substances selected from the list that comprises inositol phosphate or the pharmaceutically acceptable salts thereof, and a dialysis liquid for separate, simultaneous or sequential use in the treatment or prevention of a pathology associated with calcium disorders selected from renal lithiasis, cardiovascular calcification, calcinosis cutis, osteoporosis, calcium podagra or colon, bone or skin cancer in patients subjected to dialysis. 
Kombinirani pripravak koji sadrži, najmanje, pripravak koji sadrži tvari za inhibiciju kristalizacije odabrane s popisa koji obuhvaća inozitol fosfat ili njegove farmaceutski prikladne soli, i tekućinu za dijalizu za odvojenu, simultanu ili uzastopnu uporabu u liječenju ili prevenciji patologija povezanih s poremećajima kalcija, odabranim između bubrežne litijaze, kardiovaskularne kalcifikacije, calcinosis cutis, osteoporoze, kalcijskog gihta (podagra) ili raka kolona, kostiju ili kože bolesnicima koji se podvrgavaju dijalizi.
represents phenyl, thienyl, furyl, pyrazolyl, or pyrimidinyl, wherein: the aromatic or heterocyclic ring represented by R3 may be substituted with one or two substituents selected from the group consisting of the following substituents (1) to (14): 
predstavlja fenil, tienil, furil, pirazolil, ili pirimidinil, pri čemu: aromatski ili heterociklički prsten prikazan s R3 može biti supstituiran s jednim ili dva supstituenta odabrana iz skupine koja se sastoji od slijedećih supstituenata (1) do (14):
represents hydrogen or halogen; 
predstavlja vodik ili halogen;
represents any of the following groups (2) to (11): 
predstavlja bilo koju od slijedećih skupina (2) do (11):
represents hydrogen; and R7 represents any of the following groups (2), (7), (8) and (11): 
predstavlja vodik; i predstavlja bilo koju od slijedećih skupina (2), (7), (8) i (11):
An agent for use in the prophylactic and/or therapeutic treatment of neurodegenerative diseases diseases induced by neurological dysfunction or diseases induced by deterioration of mitochondrial function the agent comprising as an active ingredient a quinolone compound of General Formula (1) of any one of claims 1 to 3 or a salt thereof. 
Sredstvo za primjenu za profilaktičko i/ili terapeutsko liječenje neurodegenerativnih bolesti potaknutih s neurološkom disfunkcijom bolesti ili bolesti potaknutih slabljenjem funkcije mitohondrija, naznačeno time da sredstvo kao aktivni sastojak sadrži spoj kinolona s općom formulom (1) prema bilo kojem od zahtjeva 1 do 3 ili njegovu sol.
An agent for use in the prophylactic and/or therapeutic treatment according to claim 5, wherein the disease induced by neurological dysfunction is selected from the group consisting of spinal cord injury, chemotherapy-induced neuropathy, diabetic neuropathy, radiation damage, and a demyelinating disease selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, transverse myelitis, progressive multifocal leucoencephalopathy, subacute sclerosing panencephalitis, chronic inflammatory demyelinating polyneuropathy and Guillain-Barre syndrome. 
Sredstvo za primjenu za profilaktičko i/ili terapeutsko liječenje prema zahtjevu 5, naznačeno time da je bolest potaknuta neurološkom disfunkcijom odabrana iz skupine koju čine: oštećenje kičmene moždine, neuropatija potaknuta kemoterapijom, dijabetička neuropatija, oštećenje uslijed radijacije i demijelinizacijske bolesti odabrane iz skupine koju čine multipla skleroza, akutni diseminirani encefalomijelitis, transverzni mijelitis, progresivna multifokalna leukoencefalopatija, subakutni sklerozni panencefalitis, kronična inflamatorna demijelinizacijska polineuropatija i Guillain-Barreov sindrom.
A process for producing a quinolone compound represented by Formula (1b): wherein R2, R3, R4, R5, R6, and R7 are as defined in claim 1, and R1' is a group represented by R1 as defined in claim 1, or a salt thereof; the process comprising reacting a compound represented by the formula: 
Postupak za proizvodnju spoja kinolona prikazanog s Formula (1b): [image] pri čemu R2, R3, R4, R5, R6, i R7 su kako je definirano u zahtjevu 1, i R1' je skupina prikazana s R1 kako je definirano u zahtjevu 1, ili njegova sol; te postupak sadrži reakciju spoja prikazanog s formulom:
R1' -X2 wherein X2 represents a group that undergoes the same substitution reaction as that of a halogen or a halogen atom, with a compound represented by the formula: wherein R2, R3, R4, R5, R6 and R7 are as defined in claim 1. 
' -X2 pri čemu X2 predstavlja skupinu koja prolazi kroz istu supstitucijsku reakciju kao i halogen ili halogeni atom, sa spojem prikazanim s formulom: [image] pri čemu R2, R3, R4, R5, R6 i R7 su kako je definirano u zahtjevu 1.
The compound of claim 5, 6, 7 or 8 or a pharmaceutically acceptable salt thereof wherein R5 is ethyl, propyl, isopropyl, isobutyl, neopentyl, cyclopropyl, cyclobutyl, dimethylcycobutyl, cyclopentyl or cyclopropylmethyl. 
Spoj u skladu s patentnim zahtjevima 5, 6, 7 ili 8, ili njegova farmaceutski prihvatljiva sol, naznačen time što je R5 etil, propil, izopropil, izobutil, neopentil, ciklopropil, ciklobutil, dimetilciklobutil, ciklopentil ili ciklopropilmetil.
The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R1 is imidazolyl, pyrazolyl, triazolyl or indazolyl optionally substituted with one to two substituents each independently selected from methyl, trifluoromethyl, ethyl, propyl, isopropyl, butyl, t-butyl, methoxy, ethoxy, cyano, chloro or fluoro; L is -X-CHR5-; X is O; and R5 is ethyl, propyl, isopropyl, isobutyl, neopentyl, cyclopropyl, cyclobutyl, dimethylcycobutyl, cyclopentyl or cyclopropylmethyl. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je R1 imidazolil, pirazolil, triazolil ili indazolil, koji može biti supstituiran s jednim do dva supstituenta, od kojih se svakog neovisno bira između metila, trifluormetila, etila, propila, izopropila, butila, t-butila, metoksi, etoksi, cijano, klora ili fluora; L je -X-CHR5-; X je O; a R5 je etil, propil, izopropil, izobutil, neopentil, ciklopropil, ciklobutil, dimetilciklobutil, ciklopentil ili ciklopropilmetil.
"X" is CH or N; "Y" is CH2, O or or its pharmaceutically acceptable salts. 
"X" je CH ili N; "Y" je CH2, O ili [image] ili njegove farmaceutski prihvatljive soli.
The compound according to claim 1, which is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, izabrano iz grupe koja se sastoji od:
The process for preparation of a compound of formula (I) as claimed in claim 1, which comprises: 
Postupak za pripremu spoja prema formuli (I) kao se tvrdi u patentnom zahtjevu 1, koji obuhvaća:
reductive amination of the compound of formula (1) with compound of formula (2) in presence of a suitable solvent and reducing agent to form a compound of formula (I), wherein all substitutions are as defined in claim 1, 
reduktivnu aminaciju spoja prema formuli (1) sa spojem iz formule (2) [image] uz prisutnost pogodnoga rastvarača i reduktirajućeg agensa da se formira spoj iz formule (I), pri čemu sve supstitucije kako je definirano u patentnom zahtjevu 1,
A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable excipients. 
Farmaceutska supstanca obuhvaća spoj prema patentnom zahtjevu 1 farmaceutski prihvatljive ekscipijente.